摘要
目的从"毒痰瘀虚"的用药探讨中医药防治新型冠状病毒肺炎的规律。方法收集20个省市卫生部门以及专家制定防治方案,通过药物频次统计,从卫气营血传变角度探究"毒痰瘀虚"类药物防治新型冠状病毒肺炎的特点和思路。结果毒痰瘀虚的用药规律显示,中医药防治处方中,用药多偏重于"痰"、"毒"且多归于肺、脾、胃;预防期药物兼以补虚,治疗期药物兼以化瘀。结论基于"湿、毒、瘀"的主要病机,中医药防治新型冠状病毒肺炎应注重"化痰解毒",预防期药物着卫、气分,宜解表兼补虚,但不可过于寒凉,以防止治疗期瘀邪停聚入心肝之营血分。
Objective To explore the rule of treatment of Corona Virus Disease 2019(COVID-19)by traditional Chinese medicine(TCM). Methods Prevention and treatment plans issued by public health authorities and experts from 20 provinces and cities were collected to analyze hidden patterns of Chinese drug compatibility in preventing and treating COVID-19 by means of data classification in the penetration of warm disease from the surface to the centre. Results Those drugs tended to focus on"toxin","phlegm"and attributed to lung,spleen and stomach were used in the whole course. The preventive drugs focused more on"tonifying deficiency"while the therapeutic session had more drugs for"removing stasis". Conclusion In the therapeutic session of COVID-19,more attentions should be put on resolving phlegm and removing toxin on the basement of"damp-pathogen,toxin and stasis". Preventive drugs should resolve the symptoms and tonify the deficiency,but cannot be too cold to prevent"stasis"from heart and liver in therapeutic session.
作者
朱绘
李君
肖明中
吴辉坤
任朦
陶军秀
李晓东
ZHU Hui;LI Jun;XIAO Mingzhong;WU Huikun;REN Meng;TAO Junxiu;LI Xiaodong(Hubei University of Chinese Medicine,Wuhan 430065;Hubei Hospital of Traditional Chinese Medicine,Wuhan 430061;Hubei Institute of Traditional Chinese Medicine,Wuhan 430074)
出处
《湖北中医药大学学报》
2020年第3期12-16,共5页
Journal of Hubei University of Chinese Medicine
基金
国家中医药管理局科研基金项目(项目编号:JDZX2015168)
国家中医药管理局国家中医临床研究基地业务建设科研专项(项目编号:JDZX2015177)
关键词
新型冠状病毒肺炎
疫病
中医药治疗
毒痰瘀虚
COVID-19
epidemic disease
TCM treatment
toxin
phlegm
stasis and deficiency
作者简介
朱绘(1996-),女,湖北中医药大学2018级硕士研究生,研究方向:中医临床。;通讯作者:李晓东(1973-),男,湖北省中医院主任医师,研究方向:中医防治肝胆病,E-mail:lixiaodong555@126.com。
